financetom
Business
financetom
/
Business
/
Yum! Brands Q1 Adjusted Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Yum! Brands Q1 Adjusted Earnings, Revenue Rise
May 25, 2025 9:50 PM

07:34 AM EDT, 04/30/2025 (MT Newswires) -- Yum! Brands ( YUM ) reported Q1 adjusted earnings Wednesday of $1.30 per diluted share, compared with $1.15 a year earlier.

Analysts surveyed by FactSet expected $1.29.

Revenue for the quarter ended March 31 was $1.79 billion, compared with $1.60 billion a year earlier. Analysts surveyed by FactSet expected $1.85 billion.

Shares were down 1% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EU seeking feedback on draft antitrust guidelines on exclusionary abuses
EU seeking feedback on draft antitrust guidelines on exclusionary abuses
Aug 1, 2024
BRUSSELS (Reuters) - The European Commission said on Thursday it had launched a public consultation inviting all interested parties to comment on draft guidelines on exclusionary abuses of dominance, which include predatory pricing, margin squeeze, exclusive dealing and refusal to supply. In a statement, the Commission said those guidelines will help increase legal certainty to the benefit of consumers, and...
Ionis Pharmaceuticals' Q2 loss Narrows as Revenue Increases
Ionis Pharmaceuticals' Q2 loss Narrows as Revenue Increases
Aug 1, 2024
09:06 AM EDT, 08/01/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) reported a Q2 loss Thursday of $0.45 per diluted share, narrowing from a loss of $0.60 a year earlier. Analysts polled by Capital IQ expected a loss of $0.91. Revenue for the quarter ended June 30 was $225 million, up from $188 million a year earlier. Analysts surveyed...
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
Aug 1, 2024
On Wednesday, ALX Oncology Holdings Inc ( ALXO ). released topline data from its Phase 2 ASPEN-06 clinical trial. ASPEN-06 is evaluating evorpacept in combination with trastuzumab, Cyramza (ramucirumab), and paclitaxel (collectively, TRP) against TRP alone for HER2-positive gastric/GEJ cancer, where all patients had received an anti-HER2 agent in prior lines of therapy. The ASPEN-06 study is testing a new...
Southern Co beats profit estimates on customer additions, commercial demand
Southern Co beats profit estimates on customer additions, commercial demand
Aug 1, 2024
Aug 1 (Reuters) - Utility firm Southern Co ( SO ) topped Wall Street profit estimates on Thursday, helped by an uptick in the number of customers and strong commercial demand. Data center-driven demand has helped the S&P 500 Utilities sector to rise about 13% this year despite high interest rate-related expenses weighing on earnings. The company said its data...
Copyright 2023-2026 - www.financetom.com All Rights Reserved